The treatment of ovarian cancer has historically been dominated by chemotherapy, but angiogenesis and PARP inhibitors are optimizing treatment options. The regulatory approvals of Roche / Genentech’s bevacizumab (Avastin), AstraZeneca’s Lynparza, Clovis Oncology’s Rubraca, and GlaxoSmithKline / Tesaro’s Zejula are impacting physicians’ prescribing habits and creating new dynamics in treatment sequencing. Notably, the label expansions of existing therapies to the first-line maintenance setting (e.g., Lynparza plus bevacizumab maintenance for HRD-positive patients, Zejula maintenance irrespective of BRCA or HRD status) are influencing oncologists’ prescribing decision. This content will explore U.S. physicians’ prescribing behavior for ovarian cancer amid evolving treatment dynamics.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States
Primary research: Survey of 102 medical oncologists in the United States fielded in April 2021
Key drugs: Bevacizumab, Lynparza, Rubraca, Zejula